The National Cancer Institute (NCI), part of the National Institutes of Health, has released new data from the Cancer Genetic Markers of Susceptibility (CGEMS) study on prostate cancer. This information could help identify genetic factors that influence the disease and will be integral to the discovery and development of new, targeted therapies. This is also […]

The National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI), both parts of the National Institutes of Health (NIH), today announced another two of the components of The Cancer Genome Atlas (TCGA) Pilot Project, a three-year, $100 million collaboration to test the feasibility of using large-scale genome analysis technologies to identify important […]

1. What is CISNET?
The Cancer Intervention and Surveillance Modeling Network, or CISNET, is a group of researchers supported by the National Cancer Institute (NCI), part of the National Institutes of Health (NIH) (http://cisnet.cancer.gov). The group was formed to create statistical models to better understand the impact of cancer control interventions, such as screening and treatment, […]

1. What is menopausal hormone therapy?
Doctors may prescribe hormone therapy in order to alleviate symptoms associated with menopause, such as hot flashes, night sweats, sleeplessness, and vaginal dryness that occur as the body adjusts to decreased levels of estrogen. Menopausal hormone therapy (sometimes referred to as hormone replacement therapy or postmenopausal hormone use) usually involves […]

Researchers at the National Cancer Institute (NCI), part of the National Institutes of Health, have linked specific genetic mutations to defects in cells that lead to a rare disease known as Birt-Hogg-Dubé syndrome. Building on previous clinical and genetic work spanning several years, the researchers discovered a novel protein that binds to the normal version, […]